INmuneBio

About INmuneBio

INmune Bio Inc. is a clinical stage immuno-oncology company focused on harnessing the patient’s immune system to treat cancer. INKmune, the company’s lead product, primes patient’s NK cells (natural killer cells) to kill cancer. INmune is targeting residual disease, the cancer cells that survive initial treatments that return to cause the cancer relapse. By controlling residual disease, patients may live longer. Using a novel mechanism of action and a precision medicine approach, INKmune therapy should enhance NK cells’ ability to eliminate residual disease.
LEADERSHIP:
Chief Executive Officer and Chief Medical Officer: Raymond J. Tesi
Chief Financial Officer: David Moss
Chief Scientific Officer and Chief Manufacturing Officer: Mark Lowdel
PRODUCTS:
All Products
FOLLOW INMUNEBIO:
Tweets by INmuneBio